A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy

References

• Steinhardt HJ, Loeschke K, Kasper H, et al. European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. Digestion. 1985;31:97–108.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63–101.
   PubMed Web of Science ®Google Scholar
• Voderholzer WA, Beinhoelzl J, Rogalla P, et al. Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut. 2005;54:369–373.
   PubMed Web of Science ®Google Scholar
• Molinie F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988–1999). Gut. 2004;53:843–848.
   PubMed Web of Science ®Google Scholar
• Iddan GJ, Swain CP. History and development of capsule endoscopy. Gastrointest Endosc Clin N Am. 2004;14:1–9.
   PubMedGoogle Scholar
• Liangpunsakul S, Maglinte DD, Rex DK. Comparison of wireless capsule endoscopy and conventional radiologic methods in the diagnosis of small bowel disease. Gastrointest Endosc Clin N Am. 2004;14:43–50.
   PubMedGoogle Scholar
• Marmo R, Rotondano G, Piscopo R, et al. Meta-analysis: capsule enteroscopy vs. conventional modalities in diagnosis of small bowel diseases. Aliment Pharmacol Ther. 2005;22:595–604.
   PubMed Web of Science ®Google Scholar
• Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol. 2010;105:1240–1248. quiz 1249.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Coliti. 2010;4:7–27.
   PubMed Web of Science ®Google Scholar
• Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004;53:1329–1333.
   PubMed Web of Science ®Google Scholar
• Ton H, Brandsnes, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• Kronborg O, Ugstad M, Fuglerud P, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut. 2000;46:795–800.
   PubMed Web of Science ®Google Scholar
• Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol. 2003;98:2299–2305.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–647.
   PubMedGoogle Scholar
• Baveye S, Elass E, Mazurier J, et al. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999;37:281–286.
   PubMed Web of Science ®Google Scholar
• Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995;80:252–267.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32–39.
   PubMed Web of Science ®Google Scholar
• Schroder O, Naumann M, Shastri Y, et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther. 2007;26:1035–1042.
   PubMed Web of Science ®Google Scholar
• Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117–126.
   PubMed Web of Science ®Google Scholar
• Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet. 2000;356:1783–1784.
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Defranchis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008;27:146–154.
   PubMed Web of Science ®Google Scholar
• Niv Y, Ilani S, Levi Z, et al. Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy. 2012;44:21–26.
   PubMed Web of Science ®Google Scholar
• Mow WS, Lo SK, Targan SR, et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004;2:31–40.
   PubMed Web of Science ®Google Scholar
• Carter MJ, Lobo AJ, Travis SP, Ibd Section BSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:V1–16.
   Web of Science ®Google Scholar
• Timmer A, Breuer-Katschinski B, Goebell H. Time trends in the incidence and disease location of Crohn's disease 1980–1995: a prospective analysis in an urban population in Germany. Inflamm Bowel Dis. 1999;5:79–84.
   PubMed Web of Science ®Google Scholar
• Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol. 2006;101:954–964.
   PubMed Web of Science ®Google Scholar
• Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309–1314.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Yung DE, Engel T, et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepato. 2016;28:1137–1144.
   PubMed Web of Science ®Google Scholar
• Egea VJ, Pereniguez LA, Perez FV, et al. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease. Rev Esp Enferm Dig. 2016;108:394–400.
   PubMed Web of Science ®Google Scholar
• Hoog CM, Bark LA, Brostrom O, et al. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease. Scand J Gastroenterol. 2014;49:1084–1090.
   PubMed Web of Science ®Google Scholar
• Dai J, Liu WZ, Zhao YP, et al. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1440–1444.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746–1754.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Laidet M, Moussata D, et al. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease. Am J Gastroenterol. 2015;110:865–872.
   PubMed Web of Science ®Google Scholar
• Lasson A, Stotzer PO, Ohman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.
   PubMed Web of Science ®Google Scholar
• Calafat M, Cabre E, Manosa M, et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21:1072–1076.
   PubMed Web of Science ®Google Scholar
• Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37:613–621.
   PubMed Web of Science ®Google Scholar
• Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21–29.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29:485–491.
   PubMed Web of Science ®Google Scholar
• Zhou XL, Xu W, Tang XX, et al. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol. 2014;14:121. doi: 10.1186/1471-230X-14-121.
   PubMed Web of Science ®Google Scholar
• Sidhu R, Wilson P, Foye L, et al. Can faecal lactoferrin be used as a discriminator for referral for colonoscopy? Intern Med J. 2010;40:867–868.
   PubMed Web of Science ®Google Scholar
• Sidhu R, Wilson P, Wright A, et al. Faecal lactoferrin–a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther. 2010;31:1365–1370.
   PubMed Web of Science ®Google Scholar